Overview

Metformin in Parkinson Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-20
Target enrollment:
Participant gender:
Summary
The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum
Phase:
PHASE2
Details
Lead Sponsor:
Tanta University
Treatments:
carbidopa, levodopa drug combination
Metformin